Sale of sports business, a positive for Zee: The Hindu Business Line

#zee business

#

Zee Entertainment Enterprises has decided to sell its sports business (TEN Sports channels) to Sony Pictures Networks India and its affiliates for $385 million.

The sale will help Zee exit its loss-making sports broadcasting business, which contributed ₹631 crore (about 11 per cent) to its consolidated revenue in 2015-16.

The sports business incurred a net loss of ₹37 crore, against a profit of ₹1,027 crore from consolidated operations during the year.

It was in 2006 that Zee acquired a 50 per cent stake (raised subsequently) each in Taj TV, Mauritius, which owns TEN Sports channels, and in Taj Television India, the distribution arm of TEN Sports in India.

A report from Ambit Capital shows that the sports business has incurred losses at the operating level in all years except one since 2005-06.

This is in sharp contrast to the company’s profitable general entertainment channel (GEC) broadcasting business.

Zee has a strong foothold in the Hindi and regional languages GEC space, which forms a chunk of the TV viewership base. Even as it is exiting the sports genre, it is looking at expanding its presence in the regional GEC space (Tamil Nadu, for instance). In January, it acquired Sarthak TV, a leading GEC in Odisha.

TEN Sports has the broadcast rights to the events organised by the cricketing boards of five countries, including South Africa, West Indies and Pakistan, as also to other non-cricket events such as wrestling, football and tennis.

But, it does not have the broadcasting rights for some lucrative events such as the cricket matches organised by the Board of Control for Cricket in India, thereby impacting the company’s subscription revenue from this business.





Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative


#

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Summary

Background

In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was associated with significant improvements in progression-free survival compared with fulvestrant plus placebo in patients with metastatic breast cancer. Identification of patients most suitable for the addition of palbociclib to endocrine therapy after tumour recurrence is crucial for treatment optimisation in metastatic breast cancer. We aimed to confirm our earlier findings with this extended follow-up and show our results for subgroup and biomarker analyses.

Methods

In this multicentre, double-blind, randomised phase 3 study, women aged 18 years or older with hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous endocrine therapy were stratified by sensitivity to previous hormonal therapy, menopausal status, and presence of visceral metastasis at 144 centres in 17 countries. Eligible patients—ie, any menopausal status, Eastern Cooperative Oncology Group performance status 0–1, measurable disease or bone disease only, and disease relapse or progression after previous endocrine therapy for advanced disease during treatment or within 12 months of completion of adjuvant therapy—were randomly assigned (2:1) via a centralised interactive web-based and voice-based randomisation system to receive oral palbociclib (125 mg daily for 3 weeks followed by a week off over 28-day cycles) plus 500 mg fulvestrant (intramuscular injection on days 1 and 15 of cycle 1; then on day 1 of subsequent 28-day cycles) or placebo plus fulvestrant. The primary endpoint was investigator-assessed progression-free survival. Analysis was by intention to treat. We also assessed endocrine therapy resistance by clinical parameters, quantitative hormone-receptor expression, and tumour PIK3CA mutational status in circulating DNA at baseline. This study is registered with ClinicalTrials.gov. NCT01942135.

Findings

Between Oct 7, 2013, and Aug 26, 2014, 521 patients were randomly assigned, 347 to fulvestrant plus palbociclib and 174 to fulvestrant plus placebo. Study enrolment is closed and overall survival follow-up is in progress. By March 16, 2015, 259 progression-free-survival events had occurred (145 in the fulvestrant plus palbociclib group and 114 in the fulvestrant plus placebo group); median follow-up was 8·9 months (IQR 8·7–9·2). Median progression-free survival was 9·5 months (95% CI 9·2–11·0) in the fulvestrant plus palbociclib group and 4·6 months (3·5–5·6) in the fulvestrant plus placebo group (hazard ratio 0·46, 95% CI 0·36–0·59, p 0·0001). Grade 3 or 4 adverse events occurred in 251 (73%) of 345 patients in the fulvestrant plus palbociclib group and 38 (22%) of 172 patients in the fulvestrant plus placebo group. The most common grade 3 or 4 adverse events were neutropenia (223 [65%] in the fulvestrant plus palbociclib group and one [1%] in the fulvestrant plus placebo group), anaemia (ten [3%] and three [2%]), and leucopenia (95 [28%] and two [1%]). Serious adverse events (all causalities) occurred in 44 patients (13%) of 345 in the fulvestrant plus palbociclib group and 30 (17%) of 172 patients in the fulvestrant plus placebo group. PIK3CA mutation was detected in the plasma DNA of 129 (33%) of 395 patients for whom these data were available. Neither PIK3CA status nor hormone-receptor expression level significantly affected treatment response.

Interpretation

Fulvestrant plus palbociclib was associated with significant and consistent improvement in progression-free survival compared with fulvestrant plus placebo, irrespective of the degree of endocrine resistance, hormone-receptor expression level, and PIK3CA mutational status. The combination could be considered as a therapeutic option for patients with recurrent hormone-receptor-positive, HER2-negative metastatic breast cancer that has progressed on previous endocrine therapy.

Funding


Sale of sports business, a positive for Zee: The Hindu Business Line

#zee business

#

Zee Entertainment Enterprises has decided to sell its sports business (TEN Sports channels) to Sony Pictures Networks India and its affiliates for $385 million.

The sale will help Zee exit its loss-making sports broadcasting business, which contributed ₹631 crore (about 11 per cent) to its consolidated revenue in 2015-16.

The sports business incurred a net loss of ₹37 crore, against a profit of ₹1,027 crore from consolidated operations during the year.

It was in 2006 that Zee acquired a 50 per cent stake (raised subsequently) each in Taj TV, Mauritius, which owns TEN Sports channels, and in Taj Television India, the distribution arm of TEN Sports in India.

A report from Ambit Capital shows that the sports business has incurred losses at the operating level in all years except one since 2005-06.

This is in sharp contrast to the company’s profitable general entertainment channel (GEC) broadcasting business.

Zee has a strong foothold in the Hindi and regional languages GEC space, which forms a chunk of the TV viewership base. Even as it is exiting the sports genre, it is looking at expanding its presence in the regional GEC space (Tamil Nadu, for instance). In January, it acquired Sarthak TV, a leading GEC in Odisha.

TEN Sports has the broadcast rights to the events organised by the cricketing boards of five countries, including South Africa, West Indies and Pakistan, as also to other non-cricket events such as wrestling, football and tennis.

But, it does not have the broadcasting rights for some lucrative events such as the cricket matches organised by the Board of Control for Cricket in India, thereby impacting the company’s subscription revenue from this business.





Robotic Prostate Cancer Surgery Statistics #prostate, #robotic, #surgery, #prostatectomy, #cancer, #laparoscopic, #faq,


#

Robotic Prostatectomy – Prostate Removal Surgery

Prostatectomy and robotic prostate surgery are both terms for prostate removal surgery. Today, surgeons use robotic or laparoscopic prostatectomy to remove a cancerous prostate, but early methods involved traditional or open surgery.

David B. Samadi, MD, is at the forefront of prostatectomy and prostate removal surgery and has performed more than 7,000+ successful procedures to date. His innovative SMART technique uses robotic prostate surgery enhancements to improve vision and precision. In Dr. Samadi’s skilled hands, patients are assured superior quality of life results in both sex after prostate surgery and urinary control after prostate surgery.


Today’s Prostate Removal Surgery/Prostatectomy

A robotic prostatectomy requires 5 small incisions, each about one-quarter of an inch in the lower abdomen, through which instruments are inserted. A sophisticated video camera is one of the instruments, which gives Dr. Samadi a three-dimensional, 10x magnified field of vision. The keyhole incisions drastically reduce blood loss and the camera provides unprecedented visual clarity. The result is a clear surgical field during the prostatectomy with nothing to obstruct Dr. Samadi’s view of the prostate and surrounding tissue.

Cameras are also used in laparoscopic prostatectomy, but they provide only a two-dimensional image and no magnification.

Urinary Control after Prostate Surgery

Is there a risk of incontinence after prostatectomy?

Following proper prostatectomy recovery guidelines, patients who experienced normal continence prior to surgery should regain function within 12-13 months.

Loss of bladder control, or urinary incontinence, is a potential side effect of prostate removal surgery. Because the prostate sits just below the bladder and encircles the urethra, the urinary tract can be damaged during a radical prostatectomy. In the hands of an experienced robotic surgeon like Dr. Samadi, preservation of the urinary sphincter and competent rebuilding of the urinary tract can eliminate the risk of long-term incontinence. Uniquely, Dr. Samadi does not sever the endopelvic fascia and cuts the bladder neck very narrowly during robotic prostatectomy.

Urinary incontinence is far more common after open prostatectomy, as is risk of infection.

Sex after Prostate Surgery

Is there a risk of impotence after prostatectomy?

Following proper prostatectomy recovery guidelines, patients that were able to achieve sexual function before prostate surgery, 83% regained normal sexual function.

Dr. Samadi’s unique nerve-sparing technique for prostate removal surgery is crucial to preserving sexual function. These tiny nerves surrounding the prostate course laterally along the prostate and rectum and provide nerve connections to the proximal penis deep in the pelvis. If they are damaged during prostatectomy, so is erectile function. Put simply, preserving the cavernous nerves preserves sexual potency after prostate surgery. There are treatments for erectile dysfunction resulting from prostatectomy surgery, but with the right surgeon and prostate surgery technique, they are often unnecessary.

More commonly, traditional prostatectomy inadvertently results in damage to one or both of the cavernous nerves.

Prostate Surgery/Prostatectomy Recovery

Prostate surgery recovery time is substantially improved in comparison to open prostatectomy. As mentioned earlier, the much larger incision required in open surgery means pain is greater and recovery takes longer. Dr. Samadi’s prostate surgery takes just 1.5-2 hours and almost all of his patients return home the day after having a robotic prostatectomy. Around 80% of open prostatectomy patients leave the hospital within the first week.

Eradicating prostate cancer is the true measure of prostate surgery success, be it open, laparoscopic or robotic. Nowhere is the evolutionary progression more pronounced than with this marker. The positive surgical margin is the measurement used to determine whether any cancer remains or is likely to recur. A physician always seeks low positive margins. In a recent study, there was a steep drop-off in positive margins from open, to laparoscopic, to robotic. Open prostatectomy received a positive surgical margin of 23% and laparoscopic 19%, whereas robotic prostatectomy received a positive margin of only 12%.

Advanced Robotic Prostate Cancer Treatment in USA

Learn More About Prostate Cancer Treatment Options:

Call to Make an Appointment With Dr. David Samadi:

1-212-365-5000

Click the contact link to learn how Dr. Samadi can help treat your prostate cancer and give you back your quality of life.

* The benefits of robotic surgery cannot be guaranteed as surgery is both patient and procedure specific. Previous surgical results do not guarantee future outcomes.

I am aware of the fact that it takes a extraordinarily rare surgeon to be the master of Robotic Laparoscopic Radical Prostatectomy. I watched the video released by the Henri Mondor hospital before my surgery, and once again today. Although you make it seem easy to the patients and their families, your accomplishment is nearly superhuman.

I was extremely fortunate that I was blessed with the best surgeon for the job, Dr. David Samadi. It was his experience as a surgeon, a top notch team of professionals, compassion for his patients, passion for his work and a humility that is rare among people of his stature. It was this that gave me the comfort to go forward.

. , . , , . .

ברצוני להודות לך מקרב לב על הטיפול המסור, האישי והמקצועי שהענקת לי מהרגע הראשון לקשר בינינו ועד עתה. הגעתי יחד עם רעייתי אסנת לניו יורק ימים ספורים לפני ביצוע הניתוח הרובוטי לכריתת הערמונית, שהתקיים ב- 4.5.2011.

DAVID B. SAMADI, M.D. Chairman of Urology, Chief of Robotic Surgery at Lenox Hill Hospital

485 Madison avenue(between 51st-52nd street) 21st floor New York, NY 10022
Tel: 1-212-365-5000 | Fax: 1-646-692-6744


Sale of sports business, a positive for Zee: The Hindu Business Line

#zee business

#

Zee Entertainment Enterprises has decided to sell its sports business (TEN Sports channels) to Sony Pictures Networks India and its affiliates for $385 million.

The sale will help Zee exit its loss-making sports broadcasting business, which contributed ₹631 crore (about 11 per cent) to its consolidated revenue in 2015-16.

The sports business incurred a net loss of ₹37 crore, against a profit of ₹1,027 crore from consolidated operations during the year.

It was in 2006 that Zee acquired a 50 per cent stake (raised subsequently) each in Taj TV, Mauritius, which owns TEN Sports channels, and in Taj Television India, the distribution arm of TEN Sports in India.

A report from Ambit Capital shows that the sports business has incurred losses at the operating level in all years except one since 2005-06.

This is in sharp contrast to the company’s profitable general entertainment channel (GEC) broadcasting business.

Zee has a strong foothold in the Hindi and regional languages GEC space, which forms a chunk of the TV viewership base. Even as it is exiting the sports genre, it is looking at expanding its presence in the regional GEC space (Tamil Nadu, for instance). In January, it acquired Sarthak TV, a leading GEC in Odisha.

TEN Sports has the broadcast rights to the events organised by the cricketing boards of five countries, including South Africa, West Indies and Pakistan, as also to other non-cricket events such as wrestling, football and tennis.

But, it does not have the broadcasting rights for some lucrative events such as the cricket matches organised by the Board of Control for Cricket in India, thereby impacting the company’s subscription revenue from this business.





Sale of sports business, a positive for Zee: The Hindu Business Line

#zee business

#

Zee Entertainment Enterprises has decided to sell its sports business (TEN Sports channels) to Sony Pictures Networks India and its affiliates for $385 million.

The sale will help Zee exit its loss-making sports broadcasting business, which contributed ₹631 crore (about 11 per cent) to its consolidated revenue in 2015-16.

The sports business incurred a net loss of ₹37 crore, against a profit of ₹1,027 crore from consolidated operations during the year.

It was in 2006 that Zee acquired a 50 per cent stake (raised subsequently) each in Taj TV, Mauritius, which owns TEN Sports channels, and in Taj Television India, the distribution arm of TEN Sports in India.

A report from Ambit Capital shows that the sports business has incurred losses at the operating level in all years except one since 2005-06.

This is in sharp contrast to the company’s profitable general entertainment channel (GEC) broadcasting business.

Zee has a strong foothold in the Hindi and regional languages GEC space, which forms a chunk of the TV viewership base. Even as it is exiting the sports genre, it is looking at expanding its presence in the regional GEC space (Tamil Nadu, for instance). In January, it acquired Sarthak TV, a leading GEC in Odisha.

TEN Sports has the broadcast rights to the events organised by the cricketing boards of five countries, including South Africa, West Indies and Pakistan, as also to other non-cricket events such as wrestling, football and tennis.

But, it does not have the broadcasting rights for some lucrative events such as the cricket matches organised by the Board of Control for Cricket in India, thereby impacting the company’s subscription revenue from this business.





Sale of sports business, a positive for Zee: The Hindu Business Line

#zee business

#

Zee Entertainment Enterprises has decided to sell its sports business (TEN Sports channels) to Sony Pictures Networks India and its affiliates for $385 million.

The sale will help Zee exit its loss-making sports broadcasting business, which contributed ₹631 crore (about 11 per cent) to its consolidated revenue in 2015-16.

The sports business incurred a net loss of ₹37 crore, against a profit of ₹1,027 crore from consolidated operations during the year.

It was in 2006 that Zee acquired a 50 per cent stake (raised subsequently) each in Taj TV, Mauritius, which owns TEN Sports channels, and in Taj Television India, the distribution arm of TEN Sports in India.

A report from Ambit Capital shows that the sports business has incurred losses at the operating level in all years except one since 2005-06.

This is in sharp contrast to the company’s profitable general entertainment channel (GEC) broadcasting business.

Zee has a strong foothold in the Hindi and regional languages GEC space, which forms a chunk of the TV viewership base. Even as it is exiting the sports genre, it is looking at expanding its presence in the regional GEC space (Tamil Nadu, for instance). In January, it acquired Sarthak TV, a leading GEC in Odisha.

TEN Sports has the broadcast rights to the events organised by the cricketing boards of five countries, including South Africa, West Indies and Pakistan, as also to other non-cricket events such as wrestling, football and tennis.

But, it does not have the broadcasting rights for some lucrative events such as the cricket matches organised by the Board of Control for Cricket in India, thereby impacting the company’s subscription revenue from this business.